Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study-Reference-Cited by-同舟云学术

Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study

Published:2024-01-20 Issue:1 Volume:47 Page:232-239
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Saisyo Atsuyuki¹,Hashimoto Shinichi²,Ishida Haku³,Kashibe Koichi³,Oka Tomoyuki⁴,Hirano Yasushi³,Takasago Miwako¹,Uchida Yutaka¹,Okada Naoto¹,Takami Taro²,Kitahara Takashi¹

Affiliation:

1. Pharmacy Department, Yamaguchi University Hospital

2. Department of Gastroenterology and Hepatology, Yamaguchi University Hospital

3. Medical Informatics and Decision Sciences, Yamaguchi University Hospital

4. Pharmacy Department, Ube-Kohsan Central Hospital

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/1/47_b23-00682/_pdf

Reference32 articles.

1. 1) Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J. Gastroenterol., 53, 305–353 (2018).

2. 2) Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J. Gastroenterol., 56, 489–526 (2021).

3. 3) Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Correction: ACG clinical guideline: management of Crohn’s disease in adults. Am. J. Gastroenterol., 113, 1101 (2018).

4. 4) Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68 (Suppl. 3), s1–s106 (2019).

5. 5) Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin. Gastroenterol. Hepatol., 18, 2179–2191.e6 (2020).